## LAC MED BERHAD 202401049485 (1595329H)

G-03A-3, Plaza Kelana Jaya, Jalan SS7/13A, 47301 Petaling Jaya, Selangor, Malavsia.

Tel: 03-7652 1088

Ref. No.: LACMED/SC/2505-01



**PRESS RELEASE** 

## LAC Med lists on the Main Market of Bursa Malaysia Securities Berhad today

- Diversified portfolio of 11 authorised brands to drive up revenue; nine new authorised brands onboarded since 2023
- To drive adoption of Al-powered and digital solutions to optimise healthcare delivery
- Charts next phase of growth with broader range of medical offerings

Selangor, Malaysia, 10 December 2025 - Leading medical devices and integrated solutions provider, LAC Med Berhad (LAC Med or the Group; Bloomberg: LACMED MK) is charting its next phase of growth with a broader portfolio of medical devices and solutions to cater to the growing healthcare sector in Malaysia, while extending its presence in Indonesia to add new overseas revenue stream to the Group.

LAC Med made its debut on the Main Market of Bursa Malaysia Securities Berhad today. LAC Med is classified under the 'Healthcare' sector and bears the stock name of 'LACMED' with the stock code of '5341'.

Since 2023, LAC Med has added nine international brands to its portfolio, bringing the total to 11, reinforcing the Group's growth trajectory. Currently, LAC Med's portfolio covers radiographic equipment, ultrasound and MRI machines, medical consumables, software, and systems. With a wide array of offerings, the Group is well equipped to enable healthcare service providers to deliver services more efficiently, ensuring patients receive timely and quality care.

To support future revenue growth, the Group plans to expand its presence in Indonesia by progressively setting up branch offices in Sumatra, Surabaya, and Kalimantan to deliver consistent service quality and reliable technical support.

"Today's listing on the Main Market of Bursa Malaysia Securities Berhad marks a pivotal moment for LAC Med. We experienced significant growth in the second decade of our journey, building a strong presence as a leading provider of radiographic and ultrasound machines through just two authorised brands previously. As we enter the next phase with a portfolio of 11 authorised brands, we are well-poised to advance further, supported by a wider and more diversified range of offerings to propel our performance.

To strengthen our position as one of Malaysia's market leaders, we aim to drive AI-powered and digital solutions to advance the nation's healthcare sector. Our goal is to empower healthcare providers to optimise asset utilisation and patient care, while also strengthening our recurring income base to ensure sustainable, long-term growth.

Beyond Malaysia, we are pursuing new growth opportunities in Indonesia. We will leverage our two decades of experience and strong brand portfolio to mirror the success we have achieved in Malaysia and translate it into sustainable growth in the Indonesian market."

Mr. Liew Yoon Poh ("刘任堡")

Group Chief Executive Officer of LAC Med Berhad

## LAC MED BERHAD 202401049485 (1595329H)

G-03A-3, Plaza Kelana Jaya, Jalan SS7/13A, 47301 Petaling Jaya, Selangor, Malavsia.

Tel: 03-7652 1088

Ref. No.: LACMED/SC/2505-01



With an established track record built over two decades, LAC Med has served 217 hospitals nationwide, commanding a market coverage of 58%. These healthcare service providers include IHH Healthcare Group, Sunway Healthcare Group, Columbia Asia, MAHSA Hospital, and many more. Beyond hospitals, the Group has also serviced over 800 clinics across Malaysia.

LAC Med also aims to leverage its extensive experience to accelerate its expansion into Indonesia. According to the Indonesian Ministry of Health, the country had 3,228 hospitals, 10,268 public health centres, and 20,693 private clinics in 2024. The scale of Indonesia's healthcare network provides a substantial demand base for medical device distribution, positioning LAC Med to capture new opportunities in the region.

LAC Med is an authorised distributor for leading international medical brands including *Samsung and Philips*, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for *Stryker*, *LG*, *Epson*, *SwiftMR*, *Abbott*, *annalise.ai*, *Alpinion*, *Baxter* and *Bayer*.

RHB Investment Bank Berhad is the Principal Adviser, Joint Underwriter and Sole Placement Agent for the IPO, while Alliance Islamic Bank Berhad is the Joint Underwriter.

## About LAC Med Berhad (LAC Med; the Group)

Established in 2004, LAC Med is a leading medical devices and integrated solutions provider. Through its subsidiaries, LAC Med has established itself as a trusted partner to service providers in the healthcare sector. LAC Med has installed an extensive base of more than 2,500 units of medical equipment and supports over 300 active clients across Malaysia's healthcare sector, including private and public healthcare institutions, university hospitals, local health offices, medical device suppliers and concessionaire companies.

LAC Med's competencies extend from initial preliminary planning and facility design, custom interior fit-outs, equipment procurement and installation, system integration, testing and commissioning, to post-installation support services including training, technical support and maintenance services.

As an authorised distributor in Malaysia and Indonesia, LAC Med supplies and installs third-party brands of medical devices comprising medical equipment and associated products, which include medical consumables and provision of software and system integration.

LAC Med represents leading international medical brands including Samsung and Philips, with which it holds long-standing relationships since 2013 and 2017 respectively. Since 2023, the Group has also been appointed as an authorised distributor for Stryker, LG, Epson, SwiftMR, Abbott, annalise.ai, Alpinion, Baxter and Bayer, significantly strengthening its portfolio and its ability to deliver complete solutions for clients.

Issued for and on behalf of LAC MED BERHAD by Aquilas Advisory (Malaysia) Sdn Bhd. For media and investor relations enquiries, please contact:

Mr. Terence Loo <u>terence@aquilas.com.my</u> T:03-2711 1391/ M: 012-629 5618 Mr. Tee Wei Keat <u>weikeat@aquilas.com.my</u> T:03-2711 1391/ M: 012-309 5448